Good morning :)
Place Order
Add to Watchlist

Brawn Biotech Ltd

BRAWN

Brawn Biotech Ltd

BRAWN
Health CarePharmaceuticals
SmallcapWith a market cap of ₹7 cr, stock is ranked 4,580
High RiskStock is 4.24x as volatile as Nifty
24.013.22% (-0.80)
24.013.22% (-0.80)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹7 cr, stock is ranked 4,580
High RiskStock is 4.24x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹7 cr, stock is ranked 4,580
High RiskStock is 4.24x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-4.011.45—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.496.670.52%

Forecast & Ratings

Detailed Forecast 
—
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Brawn Biotech Limited is an integrated healthcare company in India, offering a wide range of pharmaceutical products including antibacterials, cardiovasculars, antifungals, and more.

Peers

Compare with peers 
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Price Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Revenue Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Earnings Per Share Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of -24.12%, vs industry avg of 9.04%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.03% to 0%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue46.8961.1755.8765.9249.7935.298.6222.2416.5813.74
Raw Materialssubtract39.9952.0748.8258.4942.1529.8911.0519.2415.5915.45
Power & Fuel Costsubtract0.010.010.030.050.050.040.020.060.08
Employee Costsubtract1.861.982.983.023.082.361.801.401.40
Selling & Administrative Expensessubtract2.922.161.742.292.071.501.811.551.76
Operating & Other expensessubtract0.673.090.250.161.531.78-4.060.28-0.86
Depreciation/Amortizationsubtract0.030.030.030.030.030.030.050.110.100.12
Interest & Other Itemssubtract0.110.070.060.070.050.040.060.010.06—
Taxes & Other Itemssubtract0.360.360.680.480.230.20-0.470.45-0.30—
EPS3.134.674.274.432.00-1.83-5.47-2.87-4.17-6.10
DPS1.001.501.000.000.000.000.000.000.000.00
Payout ratio0.320.320.230.000.000.000.000.000.000.00
See Costs

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2015

Annual report

PDF
FY 2016

Annual report

PDF
FY 2017

Annual report

PDF
FY 2018

Annual report

PDF
FY 2019

Annual report

PDF
FY 2020

Annual report

PDF
FY 2021

Annual report

PDF
FY 2022

Annual report

PDF
FY 2023

Annual report

PDF
FY 2024

Annual report

PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Brawn Biotech Ltd-5.871.45—
Sun Pharmaceutical Industries Ltd46.136.580.73%
Cipla Ltd29.214.490.87%
Mankind Pharma Ltd62.9112.57—

Price Comparison

Compare BRAWN with any stock or ETF
Compare BRAWN with any stock or ETF
BRAWN
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Increased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has increased by 2.10%

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding53.64%0.35%0.00%0.00%46.01%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.00%0.00%0.00%0.00%0.00%0.00%

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

BRAWN has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 12, 2018

Final
Final | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Sep 12, 2018

Cash Dividend

Ex DateEx DateSep 14, 2017

Final
Final | Div/Share: ₹1.50

Dividend/Share

₹1.50

Ex DateEx Date

Sep 14, 2017

News & Opinions
Earnings
Brawn Biotech reports standalone net loss of Rs 0.34 crore in the September 2024 quarter

Net Loss of Brawn Biotech reported to Rs 0.34 crore in the quarter ended September 2024 as against net loss of Rs 0.42 crore during the previous quarter ended September 2023. Sales rose 13.01% to Rs 3.30 crore in the quarter ended September 2024 as against Rs 2.92 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales3.302.92 13 OPM %-9.39-13.36 - PBDT-0.31-0.39 21 PBT-0.34-0.42 19 NP-0.34-0.42 19 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Brawn Biotech to conduct board meeting

Brawn Biotech will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Brawn Biotech to conduct AGM

Brawn Biotech announced that the 39th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Brawn Biotech reports standalone net loss of Rs 0.53 crore in the June 2024 quarter

Net Loss of Brawn Biotech reported to Rs 0.53 crore in the quarter ended June 2024 as against net loss of Rs 0.17 crore during the previous quarter ended June 2023. Sales declined 44.31% to Rs 4.06 crore in the quarter ended June 2024 as against Rs 7.29 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales4.067.29 -44 OPM %-12.32-2.06 - PBDT-0.50-0.15 -233 PBT-0.53-0.17 -212 NP-0.53-0.17 -212 Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Brawn Biotech to discuss results

Brawn Biotech will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live